↓ Skip to main content

Oncotarget

Article Metrics

Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas

Overview of attention for article published in Oncotarget, July 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#34 of 14,120)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Citations

dimensions_citation
74 Dimensions

Readers on

mendeley
57 Mendeley
Title
Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas
Published in
Oncotarget, July 2016
DOI 10.18632/oncotarget.10962
Pubmed ID
Authors

Matthew G. Field, Michael A. Durante, Christina L. Decatur, Bercin Tarlan, Kristen M. Oelschlager, John F. Stone, Jeffim Kuznetsov, Anne M. Bowcock, Stefan Kurtenbach, J. William Harbour

Abstract

We previously identified PRAME as a biomarker for metastatic risk in Class 1 uveal melanomas. In this study, we sought to define a threshold value for positive PRAME expression (PRAME+) in a large dataset, identify factors associated with PRAME expression, evaluate the prognostic value of PRAME in Class 2 uveal melanomas, and determine whether PRAME expression is associated with aberrant hypomethylation of the PRAME promoter. Among 678 samples analyzed by qPCR, 498 (73.5%) were PRAME- and 180 (26.5%) were PRAME+. Class 1 tumors were more likely to be PRAME-, whereas Class 2 tumors were more likely to be PRAME+ (P < 0.0001). PRAME expression was associated with shorter time to metastasis and melanoma specific mortality in Class 2 tumors (P = 0.01 and P = 0.02, respectively). In Class 1 tumors, PRAME expression was directly associated with SF3B1 mutations (P < 0.0001) and inversely associated with EIF1AX mutations (P = 0.004). PRAME expression was strongly associated with hypomethylation at 12 CpG sites near the PRAME promoter. Analyses included PRAME mRNA expression, Class 1 versus Class 2 status, chromosomal copy number, mutation status of BAP1, EIF1AX, GNA11, GNAQ and SF3B1, and genomic DNA methylation status. Analyses were performed on 555 de-identified samples from Castle Biosciences, 123 samples from our center, and 80 samples from the TCGA. PRAME is aberrantly hypomethylated and activated in Class 1 and Class 2 uveal melanomas and is associated with increased metastatic risk in both classes. Since PRAME has been successfully targeted for immunotherapy, it may prove to be a companion prognostic biomarker.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 1 2%
Unknown 56 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 28%
Student > Ph. D. Student 16 28%
Student > Master 4 7%
Student > Bachelor 3 5%
Other 3 5%
Other 6 11%
Unknown 9 16%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 19 33%
Medicine and Dentistry 15 26%
Agricultural and Biological Sciences 6 11%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Immunology and Microbiology 1 2%
Other 4 7%
Unknown 11 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 283. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 July 2021.
All research outputs
#91,323
of 21,546,315 outputs
Outputs from Oncotarget
#34
of 14,120 outputs
Outputs of similar age
#2,125
of 280,660 outputs
Outputs of similar age from Oncotarget
#5
of 1,091 outputs
Altmetric has tracked 21,546,315 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 14,120 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,660 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 1,091 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.